Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.

Suominen MI, Wilson T, Käkönen SM, Scholz A.

Int J Mol Sci. 2019 Aug 10;20(16). pii: E3899. doi: 10.3390/ijms20163899. Review.

2.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A.

Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

3.

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.

Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Käkönen SM, Scholz A.

J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16.

PMID:
23682134
4.

Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells.

Pollari S, Leivonen SK, Perälä M, Fey V, Käkönen SM, Kallioniemi O.

PLoS One. 2012;7(5):e37361. doi: 10.1371/journal.pone.0037361. Epub 2012 May 21.

5.

Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.

Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM.

Mol Cancer Res. 2012 May;10(5):597-604. doi: 10.1158/1541-7786.MCR-11-0482. Epub 2012 Apr 20.

6.

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.

Strube A, Suominen MI, Rissanen JP, Mumberg D, Klar U, Halleen JM, Käkönen SM.

Osteoporos Int. 2011 Nov;22(11):2887-93. doi: 10.1007/s00198-010-1486-9. Epub 2010 Nov 23.

PMID:
21104229
7.

D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model.

Zitzmann-Kolbe S, Strube A, Frisk AL, Käkönen SM, Tsukada H, Hauff P, Berndorff D, Graham K.

J Nucl Med. 2010 Oct;51(10):1632-6. doi: 10.2967/jnumed.110.078899. Epub 2010 Sep 16.

8.

Characterization of a new renal cell carcinoma bone metastasis mouse model.

Strube A, Stepina E, Mumberg D, Scholz A, Hauff P, Käkönen SM.

Clin Exp Metastasis. 2010 May;27(5):319-30. doi: 10.1007/s10585-010-9329-9. Epub 2010 May 5.

PMID:
20443133
9.

Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.

Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O.

Breast Cancer Res Treat. 2011 Jan;125(2):421-30. doi: 10.1007/s10549-010-0848-5. Epub 2010 Mar 30. Erratum in: Breast Cancer Res Treat. 2012 Feb;131(3):1085-6.

PMID:
20352489
10.

Luminescent imaging technology as an opportunity to reduce and refine animal experiments: Light at the end of the tunnel?

Hagelschuer I, Hauff P, Strube A, Käkönen SM, von Degenfeld G.

ALTEX. 2009;26(3):177-85.

11.

Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.

Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM.

Clin Cancer Res. 2009 Jun 1;15(11):3751-9. doi: 10.1158/1078-0432.CCR-08-3123. Epub 2009 May 26.

12.

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

Borgenström M, Wärri A, Hiilesvuo K, Käkönen R, Käkönen S, Nissinen L, Pihlavisto M, Marjamäki A, Vlodavsky I, Naggi A, Torri G, Casu B, Veromaa T, Salmivirta M, Elenius K.

Semin Thromb Hemost. 2007 Jul;33(5):547-56.

PMID:
17629853
13.

Urinary osteocalcin as a marker of bone metabolism.

Ivaska KK, Käkönen SM, Gerdhem P, Obrant KJ, Pettersson K, Väänänen HK.

Clin Chem. 2005 Mar;51(3):618-28. Epub 2005 Jan 13.

14.

Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis.

Akesson K, Käkönen SM, Josefsson PO, Karlsson MK, Obrant KJ, Pettersson K.

J Bone Miner Metab. 2005;23(1):30-5.

PMID:
15616891
15.

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA.

Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9. Epub 2003 Aug 26.

16.

A multigenic program mediating breast cancer metastasis to bone.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J.

Cancer Cell. 2003 Jun;3(6):537-49.

17.

Identification of novel proteolytic forms of osteocalcin in human urine.

Ivaska KK, Hellman J, Likojärvi J, Käkönen SM, Gerdhem P, Akesson K, Obrant KJ, Pettersson K, Väänänen HK.

Biochem Biophys Res Commun. 2003 Jul 11;306(4):973-80.

PMID:
12821138
18.

Mechanisms of osteolytic bone metastases in breast carcinoma.

Käkönen SM, Mundy GR.

Cancer. 2003 Feb 1;97(3 Suppl):834-9. Review.

19.

Characteristics and composition of the vitamin K-dependent gamma-glutamyl carboxylase-binding domain on osteocalcin.

Houben RJ, Rijkers DT, Stanley TB, Acher F, Azerad R, Käkönen SM, Vermeer C, Soute BA.

Biochem J. 2002 May 15;364(Pt 1):323-8.

20.

Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.

Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA.

J Biol Chem. 2002 Jul 5;277(27):24571-8. Epub 2002 Apr 18.

Supplemental Content

Loading ...
Support Center